Quick Answer
Tirzepatide (Zepbound) is the most effective approved peptide for weight loss: people lost up to 20.9% of their body weight on average in its main trial. Semaglutide (Wegovy) comes next at about 15%, or about 21% on the newer 7.2 mg dose, and it is also available as a daily pill. Retatrutide, which is still in trials, reached 28.3%. Popular online peptides such as AOD-9604 and MOTS-c have not been shown to cause weight loss in people.
Weight loss peptides went from a niche topic to one of the most searched subjects in medicine in about five years. The term now covers two very different groups. One is a small set of prescription medicines, led by semaglutide and tirzepatide, that have been tested in trials of thousands of people and approved by FDA. The other is a long list of "research peptides" sold online, most of which have never been shown to cause weight loss in a human trial.
This guide covers both groups. For each peptide, we show how much weight people actually lost in trials, its FDA status, who it suits and what to watch for. We also cover what happens when you stop, how to protect muscle, what the medicines cost and which ones are worth waiting for.
Key Takeaways
- Tirzepatide produced the largest average weight loss of any approved medicine: 20.9% at 72 weeks on the highest dose.
- In the only head-to-head trial, tirzepatide beat semaglutide by 20.2% to 13.7% at 72 weeks.
- Semaglutide is the only weight loss peptide proven to reduce heart attacks and strokes, by 20% in people with heart disease.
- A daily semaglutide pill was approved in December 2025, with 13.6% average weight loss in its trial.
- Retatrutide and CagriSema are the next generation, but neither is approved yet.
- AOD-9604, the best-known online "fat loss peptide", did not cause significant weight loss in a 536-person trial.
- Most people regain much of the weight after stopping, so these medicines work best as long-term treatment.
How We Built This List
Each peptide is ranked on how much weight people lost in large, placebo-controlled trials, whether FDA has approved it for weight loss, and how much is known about its long-term safety. Approved medicines rank above pipeline drugs, even when a pipeline drug lost more weight, because approval means the full safety and manufacturing data have been reviewed.
We used published trials, FDA labels and FDA announcements as of November 2026, and our physician reviewed every entry. A higher rank means stronger evidence. It is not a recommendation to use a specific medicine, which depends on your health, goals and coverage.
Weight Loss Peptides at a Glance
Four peptide medicines are FDA-approved for chronic weight management: tirzepatide, semaglutide injection, semaglutide pill and liraglutide. Two more, retatrutide and CagriSema, have finished major trials. The rest of the peptides marketed for weight loss have little or no human weight loss data.
Average Weight Loss in Each Main Trial
How Weight Loss Peptides Work
The approved weight loss peptides are lab-made versions of gut hormones that the body releases after a meal. They act on the brain to reduce hunger and food noise, slow how quickly the stomach empties so you feel full sooner, and help the body handle blood sugar. Each new generation adds another hormone signal, and average weight loss has risen with each one.
GLP-1 (glucagon-like peptide-1) is the first and best-studied signal. Tirzepatide adds GIP, a second gut hormone. Retatrutide adds a third, glucagon, which may increase how much energy the body burns. CagriSema pairs semaglutide with cagrilintide, a long-acting version of amylin, a fullness hormone released by the pancreas.
From One Hormone to Three
Best Peptides for Weight Loss, Ranked
The list starts with the approved medicine that produced the most weight loss and ends with peptides that have no proven effect. For each one, we show the weight loss in trials, its status, what it is, what the research shows, who it suits and its limitations.
1. Tirzepatide (Zepbound): The Most Effective Approved Peptide
- Average weight loss: 15.0% to 20.9% at 72 weeks, depending on dose, vs 3.1% on placebo
- FDA status: Approved for chronic weight management in November 2023, and for moderate to severe obstructive sleep apnea in adults with obesity in December 2024. Sold as Mounjaro for type 2 diabetes
What it is: A weekly injection that activates two gut hormone receptors, GLP-1 and GIP. It was the first dual-hormone weight loss medicine.
What the research shows: In SURMOUNT-1, 2,539 adults with obesity or overweight lost an average of 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks, compared with 3.1% on placebo. In SURMOUNT-5, the first head-to-head trial against semaglutide, people on tirzepatide lost 20.2% of their weight vs 13.7% on semaglutide.
Best for: Adults who want the largest average weight loss among approved options, and adults with obesity and sleep apnea. See our guide to peptides for sleep for more on the sleep apnea approval.
Limitations and side effects: Nausea, diarrhea, constipation and vomiting are common, mostly while the dose is being raised. Tirzepatide can make birth control pills less effective. It has not been shown to reduce heart attacks and strokes the way semaglutide has, although a large trial is underway.
2. Semaglutide Injection (Wegovy): The Most Studied, With Heart Protection
- Average weight loss: 14.9% at 68 weeks on 2.4 mg, vs 2.4% on placebo. 20.7% at 72 weeks on the 7.2 mg dose
- FDA status: Approved for chronic weight management in June 2021, and to reduce heart attack, stroke and cardiovascular death in March 2024. The higher 7.2 mg dose, Wegovy HD, was approved in March 2026. Sold as Ozempic for type 2 diabetes
What it is: A weekly GLP-1 injection, and the medicine that started the current era of weight loss treatment.
What the research shows: In STEP 1, 1,961 adults lost an average of 14.9% on semaglutide 2.4 mg, compared with 2.4% on placebo. In SELECT, a trial of 17,604 adults with heart disease and overweight or obesity, semaglutide cut major cardiovascular events such as heart attack and stroke by 20%. In STEP UP, 1,407 adults on the 7.2 mg dose lost an average of 20.7%. That dose is for people who have tolerated 2.4 mg and need more effect.
Best for: Adults with heart disease and excess weight, who gain a proven heart benefit, and anyone who wants the medicine with the longest safety record. Read our in-depth guide to semaglutide injections.
Limitations and side effects: In STEP 1, 44% of people on semaglutide had nausea, compared with 17% on placebo, though it was usually mild to moderate and faded over time. The label advises stopping at least 2 months before a planned pregnancy.
Head to Head: Tirzepatide vs Semaglutide
3. Semaglutide Pill (Wegovy Pill): The First Peptide Weight Loss Pill
- Average weight loss: 13.6% at 64 weeks, vs 2.2% on placebo
- FDA status: Approved for chronic weight management in December 2025
What it is: A once-daily 25 mg semaglutide tablet. Peptides are normally broken down in the stomach, so the pill includes an absorption enhancer and must be taken on an empty stomach with a small sip of water, at least 30 minutes before eating.
What the research shows: In OASIS 4, 307 adults lost an average of 13.6% over 64 weeks, compared with 2.2% on placebo, which is close to the results of the weekly injection.
Best for: People who would rather not inject and can follow the morning routine every day.
Limitations and side effects: The same stomach side effects as the injection. Absorption drops if it is taken with food or too much water, so timing matters.
4. Liraglutide (Saxenda): The Original, Now Generic
- Average weight loss: 8.0% at 56 weeks, vs 2.6% on placebo
- FDA status: Approved for chronic weight management in December 2014. A generic version became available in 2025. Sold as Victoza for type 2 diabetes
What it is: The first GLP-1 approved for weight loss, given as a daily injection.
What the research shows: In the SCALE trial of 3,731 adults, liraglutide 3 mg produced 8.0% average weight loss over 56 weeks, compared with 2.6% on placebo.
Best for: People whose plan covers it but not the newer drugs, and those who prefer a lower-cost generic.
Limitations and side effects: About half the weight loss of semaglutide, and it needs a daily injection.
A note on pills: orforglipron (Foundayo), approved in April 2026, is a daily GLP-1 pill, but it is a small molecule, not a peptide, so it is not ranked here. In its main trial, ATTAIN-1, people on the highest dose lost an average of 11.2% at 72 weeks, compared with 2.1% on placebo. Unlike the semaglutide pill, it can be taken without food or water restrictions.
5. Retatrutide: The Strongest Result So Far, Not Yet Approved
- Average weight loss: 28.3% at 80 weeks on 12 mg, in TRIUMPH-1
- FDA status: Not approved. Eli Lilly plans to file for approval in early 2027
What it is: A weekly injection that activates three hormone receptors: GLP-1, GIP and glucagon. It is sometimes called a "triple agonist".
What the research shows: In TRIUMPH-1, reported by Eli Lilly in May 2026, people on the highest dose lost an average of 28.3% of their body weight over 80 weeks. That is the largest average weight loss reported in a phase 3 trial of any weight loss medicine.
Best for: Not available outside clinical trials. It may become an option for people who need more weight loss than current medicines provide.
Limitations: Long-term safety is still being reviewed. Retatrutide sold online as a "research peptide" is not the drug tested in trials, and its contents, purity and dose cannot be verified.
6. CagriSema: Semaglutide Plus Amylin, Under FDA Review
- Average weight loss: 20.4% at 68 weeks, vs 3.0% on placebo
- FDA status: Not approved. Novo Nordisk filed for approval in December 2025, and a decision is expected in late 2026
What it is: A weekly injection that combines semaglutide with cagrilintide, a long-acting version of the fullness hormone amylin.
What the research shows: In REDEFINE 1, adults lost an average of 20.4% over 68 weeks. In a head-to-head trial against tirzepatide, CagriSema produced 23.0% average weight loss vs 25.5% for tirzepatide and did not meet its goal of matching it.
Best for: If approved, people who want a semaglutide-based option with more effect than semaglutide alone.
Limitations: Not yet available. It did not match tirzepatide head to head.
7. Tesamorelin (Egrifta): Belly Fat in HIV, Not General Weight Loss
- Average weight loss: Not a weight loss drug. It reduced deep belly fat by about 15% in its trials
- FDA status: Approved only to reduce excess belly fat in people with HIV who have lipodystrophy, a condition that changes where fat is stored
What it is: A daily injection that copies growth hormone-releasing hormone, the brain's signal for releasing growth hormone.
What the research shows: In people with HIV, tesamorelin reduced visceral fat, the fat around the organs, by about 15% over 26 weeks. Total body weight barely changed, and the fat returned after stopping.
Best for: People with HIV-related belly fat. It has not been approved or properly tested for general weight loss.
Limitations and side effects: Joint pain, swelling and higher blood sugar. Not studied for weight loss in people without HIV.
8. AOD-9604: Tested, and Did Not Work
- Average weight loss: No significant difference from placebo in its largest trial
- FDA status: Not approved. Sold online as a research chemical
What it is: A small fragment of human growth hormone, designed to break down fat without the other effects of growth hormone.
What the research shows: AOD-9604 is the most heavily marketed online "fat loss peptide", and it is also one of the few that was properly tested. In a 24-week trial of 536 adults with obesity, it did not produce significant weight loss compared with placebo, and its developer stopped work on it for obesity in 2007.
Best for: We found no group for which there is good evidence.
Limitations: No proven weight loss in people. Online products are not tested for purity, strength or sterility.
9. MOTS-c, CJC-1295, Ipamorelin and BPC-157: No Human Weight Loss Trials
- Average weight loss: Unknown. No published human weight loss trials
- FDA status: None is approved. All are sold online as research chemicals
What they are: MOTS-c is a peptide made by mitochondria, studied for metabolism in mice. CJC-1295 and ipamorelin raise growth hormone. BPC-157 is promoted for healing.
What the research shows: MOTS-c reduced weight gain in mice fed a high-fat diet. Growth hormone peptides raise growth hormone and IGF-1 levels, but that has not been shown to cause meaningful fat loss in a controlled trial. BPC-157 has no weight loss research. For more on these peptides, see our guide to peptides for muscle growth.
Limitations: No human weight loss data, and the contents of products bought online cannot be verified.
A note on our role: Unify Care's physicians prescribe FDA-approved weight loss medicines when they are medically appropriate. We do not prescribe, sell, supply or source research peptides such as AOD-9604, MOTS-c or retatrutide sold online..
Brand Names Decoded: Ozempic, Wegovy, Mounjaro and Zepbound
Ozempic and Wegovy are the same medicine, semaglutide, and Mounjaro and Zepbound are the same medicine, tirzepatide. The difference is the approved use and the dose. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are approved for weight management.
Weight Loss Peptides and Their Brand Names
Semaglutide vs Tirzepatide for Weight Loss
Tirzepatide produces more weight loss on average, about 20% vs 14% in the head-to-head trial, while semaglutide has proven heart protection and comes as a pill. Both are weekly injections with similar side effects. The better choice depends on your goals, your heart risk and what your plan covers.
For a deeper comparison of dosing, side effects and switching between the two, read our full guide to tirzepatide vs semaglutide.
What Is Approved, and What Is Coming
In just over a decade, average weight loss from approved peptides has gone from about 8% to about 21%, and the next medicines may reach close to 30%.
Weight Loss Medicine Timeline
What Happens When You Stop a Weight Loss Peptide
Most people regain a large share of the weight within a year of stopping. In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of their body weight, while those who stayed on it kept losing.
Weight After Stopping, in Two Trials
This happens because the medicines treat obesity rather than cure it. When the hormone signal stops, appetite returns. That is why doctors now view these medicines as long-term treatment, similar to blood pressure medicine. Some people step down to a lower maintenance dose, and building strength training and protein habits while on treatment can help you keep more of the result.
Muscle Loss on GLP-1 Peptides
Some of the weight lost on these medicines is lean mass, including muscle. In a body scan substudy of STEP 1, about 40% of the weight lost on semaglutide was lean mass. That share is similar to what happens with diet-only weight loss, but because the total loss is larger, so is the lean mass lost.
Two habits make the biggest difference. The first is strength training at least two to three times a week. The second is eating enough protein, commonly 1.2 to 1.6 grams per kilogram of body weight a day while losing weight, spread across meals. No peptide has been proven to prevent muscle loss on a GLP-1. Read more in our guide to peptides for muscle growth.
Hair Shedding on GLP-1 Peptides
Some people notice hair shedding a few months into treatment. It is usually telogen effluvium, temporary shedding triggered by rapid weight loss, and it typically settles as weight stabilizes.
Enough protein, a slower rate of loss and checking iron and thyroid levels help. See our guide to peptides for hair growth for what does and does not help.
Compounded and Research Peptides: What to Know
Compounded semaglutide and tirzepatide are not FDA-approved, and research peptides sold online are not meant for people at all. These are the two biggest sources of confusion, and of risk, in weight loss peptides.
Compounded GLP-1s. During the shortages of 2022 to 2024, FDA allowed pharmacies to make copies of semaglutide and tirzepatide. FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025, and the grace periods for making mass copies ended in 2025. Compounded versions have not been reviewed by FDA for safety, quality or effect, and FDA has received reports of dosing errors, especially with multi-dose vials. Some products use salt forms, such as semaglutide sodium, which are not the ingredient in the approved medicines.
Research peptides. Retatrutide, AOD-9604, MOTS-c and even semaglutide and tirzepatide are sold online labeled "for research use only, not for human consumption". FDA has warned sellers of these products. They have no checks on purity, strength, sterility, or even what is in the vial.
How Much Do Weight Loss Peptides Cost?
Self-pay prices have fallen sharply, and in November 2026 approved GLP-1 medicines start at about $149 to $349 a month through the manufacturers' direct programs. Insurance coverage for weight loss still varies widely by plan.
Approximate Monthly Self-Pay Prices, November 2026
Many commercial plans cover Wegovy or Zepbound for weight loss, but often with prior authorization and BMI rules. Medicare cannot cover medicines used only for weight loss, but it can cover Wegovy to lower heart risk in people with heart disease, and Zepbound for sleep apnea. Ask your plan which drug is preferred before you start, because switching later can be harder.
Who Is a Candidate for Weight Loss Peptides?
FDA-approved weight loss peptides are for adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Wegovy and Saxenda are also approved for children aged 12 and older with obesity.
These medicines are used together with a reduced-calorie diet and more physical activity. Your physician will also consider your medical history, other medicines and goals.
Who should not take them:
- Anyone with a personal or family history of medullary thyroid cancer, or multiple endocrine neoplasia type 2 (MEN2)
- Anyone who is pregnant, or trying to become pregnant
- Anyone who has had a serious allergic reaction to the medicine
Who needs extra care: people with a history of pancreatitis, gallbladder disease, diabetic eye disease, kidney problems or an eating disorder, and people taking insulin or sulfonylureas, which can cause low blood sugar together with a GLP-1. If you have surgery planned, tell your surgeon and anesthesiologist, because these medicines slow stomach emptying.
What Women Should Know
Women need to plan around three things: birth control, pregnancy and menopause.
- Birth control. Tirzepatide can make birth control pills less effective. The label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase.
- Pregnancy. None of these medicines should be used during pregnancy. The semaglutide label advises stopping at least 2 months before a planned pregnancy. Weight loss can improve fertility, especially in women with polycystic ovary syndrome, so reliable contraception matters.
- Menopause. Hormonal changes in perimenopause and menopause can make weight harder to manage, and weight loss medicines can be part of a broader plan that may include hormone replacement therapy.
Side Effects and Safety
Stomach side effects such as nausea, diarrhea, constipation and vomiting are the most common, and they are usually worst in the first weeks and after each dose increase. Raising the dose slowly, eating smaller meals and avoiding greasy food usually help.
FDA Label Warnings
- Thyroid C-cell tumors. Semaglutide, tirzepatide and liraglutide carry a boxed warning because they caused thyroid tumors in rodents. It is not known whether this happens in people.
- Pancreatitis. Inflammation of the pancreas has been reported. Severe belly pain needs urgent evaluation.
- Gallbladder problems. Gallstones are more common, partly because of rapid weight loss.
- Kidney problems. Dehydration from vomiting or diarrhea can strain the kidneys.
- Low blood sugar. The risk is higher when combined with insulin or sulfonylureas.
Research peptides bought online carry additional risks of infection, contamination and wrong doses, because nobody checks what is in the vial.
Which Option Matches Your Situation?
The best weight loss peptide is the one that fits your health, goals and coverage. These are common starting points for a conversation with your physician.
Match Your Situation to an Option
Medical Weight Loss at Unify Care
Our physicians offer supervised medical weight loss, at home or by telehealth, with the time to adjust treatment as you go.
- A full evaluation. We review your history, medicines and labs to see which options are safe and likely to work for you.
- FDA-approved medicines. When medically appropriate, we prescribe FDA-approved GLP-1 medicines as part of our medical weight loss program, and monitor side effects, dose and progress.
- Muscle, nutrition and maintenance. We help you protect muscle, manage side effects and plan for the long term.
- Peptide questions. Our peptide consultation explains what the research on a specific peptide does and does not show.
We do not prescribe, sell, supply or source research peptides. Our concierge membership gives you direct access to your physician across Orange County, Los Angeles, Riverside, San Bernardino, Palm Springs and San Diego.
Frequently Asked Questions
What is the best peptide for weight loss?
Tirzepatide (Zepbound) produced the largest average weight loss of any approved medicine, up to 20.9% at 72 weeks, and it beat semaglutide in a head-to-head trial. Semaglutide (Wegovy) is the best choice for many people with heart disease, because it is proven to reduce heart attacks and strokes.
Is semaglutide or tirzepatide better for weight loss?
Tirzepatide produced more weight loss in the SURMOUNT-5 head-to-head trial, 20.2% vs 13.7% at 72 weeks. Semaglutide has proven heart protection, a higher 7.2 mg dose and a pill form. Side effects are similar.
How much weight can you lose with peptides?
In their main trials, average weight loss was about 8% with liraglutide, about 14 to 15% with semaglutide 2.4 mg and its pill, and about 21% with tirzepatide and semaglutide 7.2 mg. Results vary widely, and some people lose much more or much less than average.
Do peptides like AOD-9604 or MOTS-c work for weight loss?
There is no good evidence that they do. AOD-9604 did not produce significant weight loss compared with placebo in a 24-week trial of 536 adults. MOTS-c has only been studied for weight in mice. Neither is FDA-approved.
What is retatrutide, and when will it be available?
Retatrutide is a weekly injection that acts on three hormone receptors: GLP-1, GIP and glucagon. In its first phase 3 trial, people lost an average of 28.3% at 80 weeks. It is not approved, and Eli Lilly plans to file for FDA approval in early 2027.
Is there a peptide pill for weight loss?
Yes. The Wegovy pill, a daily 25 mg semaglutide tablet, was approved in December 2025. In its main trial, people lost an average of 13.6% at 64 weeks. Orforglipron (Foundayo) is another daily weight loss pill, but it is not a peptide.
What happens when you stop taking a GLP-1?
Most people regain a large share of the weight. In the STEP 1 extension, people regained about two-thirds of their lost weight within a year of stopping semaglutide. These medicines work best as long-term treatment.
Are compounded semaglutide and tirzepatide safe?
Compounded versions are not FDA-approved, so their safety, quality and strength have not been reviewed by FDA. The national shortages ended in 2024 and 2025, and FDA has received reports of dosing errors with compounded products.
How much do weight loss peptides cost without insurance?
As of November 2026, manufacturer self-pay prices start at about $299 a month for Zepbound vials, $199 to $349 a month for Wegovy pens and $149 a month for starting doses of the Wegovy pill. Prices change often.
Do GLP-1 peptides cause muscle loss?
Some of the weight lost is lean mass. In a STEP 1 body scan substudy, about 40% of the weight lost on semaglutide was lean mass. Strength training and enough protein help protect muscle.
Who should not take GLP-1 weight loss medicines?
People with a personal or family history of medullary thyroid cancer or MEN2, people who are pregnant or trying to conceive, and anyone who has had a serious allergic reaction to the medicine. People with a history of pancreatitis or gallbladder disease need extra caution.
Does Unify Care prescribe weight loss peptides?
Unify Care's physicians prescribe FDA-approved GLP-1 medicines when medically appropriate, as part of a supervised weight loss program. We do not prescribe, sell, supply or source research peptides such as AOD-9604, MOTS-c or retatrutide sold online.
Book an appointment or call (949) 979-6956 to talk with a physician about medical weight loss.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Trial results are averages and individual results vary. Prices are approximate as of November 2026. Talk to a qualified physician before starting, stopping or changing any treatment.
Sources
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.
- Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025.
- Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015;373:11–22.
- Novo Nordisk. FDA approval of Wegovy 7.2 mg, and STEP UP trial results. March 2026.
- Eli Lilly and Company. Retatrutide TRIUMPH-1 phase 3 topline results. May 21, 2026.
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025.
- Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1). N Engl J Med. 2025.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–1564.
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331:38–48.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359–2370.
- Metabolic Pharmaceuticals. AOD9604 OPTIONS phase 2b trial results. 2007.
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2025.
- US Food and Drug Administration. Prescribing information for Zepbound (tirzepatide), Wegovy (semaglutide) and Saxenda (liraglutide).
